<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01372085</url>
  </required_header>
  <id_info>
    <org_study_id>14318</org_study_id>
    <secondary_id>I3G-FW-JGCE</secondary_id>
    <nct_id>NCT01372085</nct_id>
  </id_info>
  <brief_title>Single Dose Study in Healthy Participants to Investigate the Safety and Absorption of LY2584702</brief_title>
  <official_title>A Single Ascending Dose and Relative Bioavailability Study of LY2584702 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centre, placebo-controlled, two-part study in healthy participants.

      Part A will be a single dose, single period, placebo-controlled pilot study to explore the
      safety, tolerability, absorption and pharmacodynamic [effect of drug on a biological
      marker-phospho-S6 (pS6) levels in skin biopsies] of a single dose of 25 milligrams (mg)
      LY2584702 Reference formulation (RF). Part B is a single dose, placebo-controlled, 4-period
      crossover study to primarily evaluate the absorption of the Test Formulation (TF) in
      comparison with the (RF) of LY2584702.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Part A: Day 1 and Part B: Periods 1 to 4, Day 1 [Predose, 1 hour (h), 3 h, 4 h, 6 h, 10 h, 24 h, 48 h postdose]</time_frame>
    <description>The Cmax following a single oral dose of LY2584702 test formulation [TF (tablet)] or reference formulation [RF (capsule)] is reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, Area Under the Concentration-Time Curve (AUC)</measure>
    <time_frame>Part A: Day 1 and Part B: Periods 1 to 4, Day 1 [Predose, 1 hour (h), 3 h, 4 h, 6 h, 10 h, 24 h, 48 h postdose]</time_frame>
    <description>AUC from time 0 to the time of the last quantifiable concentration [AUC(0-tlast)] and AUC from time 0 to infinity [AUC(0-inf)] following a single oral dose of LY2584702 test formulation [TF (tablet)] or reference formulation [RF (capsule)] is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Baseline-Adjusted Change-From-Predose in the Concentration of Lipids (Total Cholesterol)</measure>
    <time_frame>Part B: Baseline [Periods 1 and 4a (Day -1)], Periods 3, 4a (Day 1). Lipid concentration measurements were performed at time point 0 and 1 hour (h), 3 h, 4 h, 6 h, 10 h, and 24 h.</time_frame>
    <description>Baseline-adjusted change-from-predose in lipid concentrations were measured to assess the LY2584702 effect on lipids under different fed states. The 50-milligram (mg) LY2584702 test formulation [TF (tablet)] was the only dose and formulation administered in both the fasted and fed states for comparison. Therefore, changes in total cholesterol after single oral doses of placebo, 10-mg, or 200-mg LY2584702 TF or 25-mg or 50-mg LY2584702 reference formulation [RF (capsule)] were not calculated. The baseline-adjusted change-from-predose in total cholesterol levels in the fasted and fed state following a single 50-mg LY2584702 TF dose is reported. Baseline was Day -1 of Period 1 for Period 3 fasted state and baseline was Day -1 of Period 4a for Period 4a fed state. Least squares (LS) means was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, time, treatment by time, and participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: QT Interval Corrected by Fridericia's Formula (QTcF) Change From Baseline to Day 1</measure>
    <time_frame>Part A: Baseline [Day 1 (Predose)] and Day 1 (3 h, 4 h, 6 h, and 24 h postdose)</time_frame>
    <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and is calculated from electrocardiogram (ECG) data. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between 2 R waves. Using Fridericia's formula: QTcF = QT/RR^0.33. The QTcF after single oral doses of LY2584702 reference formulation [RF (capsule)] were administered in a fasted state are reported at baseline (Day 1, Predose) and 3 hours (h), 4 h, 6 h, and 24 h postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Average Time-Matched QT Interval Corrected by Fridericia's Formula (QTcF) Change From Baseline to Day 1</measure>
    <time_frame>Part B: Baseline [Period 1 (Day -1)] and Periods 1 to 4 (Day 1). Electrocardiograms (ECG) were performed at time point 0 and 3 h, 4 h, 6 h, and 24 h.</time_frame>
    <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and is calculated from electrocardiogram (ECG) data. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between 2 R waves. Using Fridericia's formula: QTcF = QT/RR^0.33. The QTcF after single oral doses of LY2584702 test formulation [TF (tablet)], LY2584702 reference formulation [RF (capsule)], or placebo were administered in a fasted or fed state are reported at baseline (time-matched Day -1 QTcF) and 3 hours (h), 4 h, 6 h, and 24 h postdose. Day 1, Hour 24 was time-matched with Day-1, Hour 0.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Part A: 25 mg RF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 25 mg dose of LY2584702 RF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo taken orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 10 mg dose of LY2584702 TF during the first intervention period, followed by placebo in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 10 mg dose of LY2584702 TF during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 10 mg dose of LY2584702 TF during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by placebo in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2584702 Reference Formulation</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part A: 25 mg RF</arm_group_label>
    <arm_group_label>Part B: Sequence 2</arm_group_label>
    <arm_group_label>Part B: Sequence 3</arm_group_label>
    <arm_group_label>Part B: Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2584702 Test Formulation</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part B: Sequence 1</arm_group_label>
    <arm_group_label>Part B: Sequence 2</arm_group_label>
    <arm_group_label>Part B: Sequence 3</arm_group_label>
    <arm_group_label>Part B: Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_label>Part B: Sequence 1</arm_group_label>
    <arm_group_label>Part B: Sequence 2</arm_group_label>
    <arm_group_label>Part B: Sequence 3</arm_group_label>
    <arm_group_label>Part B: Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male participants:

        • Agree to use a reliable method of birth control during the study and for at least 1 month
        following the last dose of study drug

        Female participants:

        • Women not of childbearing potential due to surgical sterilization (hysterectomy or
        bilateral oophorectomy or tubal ligation) or menopause. Women with an intact uterus are
        deemed postmenopausal if they are greater than or equal to 45 years old, who have not taken
        hormones or oral contraceptives within the last year, and had cessation of menses for at
        least 1 year, or who have had 6 to 12 months of amenorrhea with follicle-stimulating
        hormone (FSH) levels consistent with postmenopausal state.

        All participants:

          -  have a screening body mass index (BMI) of 18.5 to 32.0 kilograms per square meter
             (kg/m^2), inclusive

          -  have clinical laboratory test results within the normal range for the population or
             investigator site, or with abnormalities deemed clinically insignificant by the
             investigator. In particular, participants should have normal or near normal screening
             liver tests at the discretion of the investigator

          -  have normal blood pressure and pulse rate (supine) at screening, or with minor
             deviations judged to be acceptable by the investigator

          -  have venous access sufficient to allow blood sampling as per the protocol

          -  are reliable and willing to make themselves available for the duration of the study
             and are willing to follow study procedures

          -  have given written informed consent approved by Lilly and the ethical review board
             (ERB) governing the site

        Exclusion Criteria

        All participants:

          -  are currently enrolled in, have completed or discontinued within the last 30 days
             from, a clinical trial involving an investigational product other than the
             investigational product used in this study; or are concurrently enrolled in any other
             type of medical research judged not to be scientifically or medically compatible with
             this study. Participants that participate in Part A of this study may participate in
             Part B of the study if the first dosing in Part B is &gt;30 days after the dose of
             LY2584702 or placebo in Part A.

          -  have known allergies to LY2584702, or related compounds

          -  have an abnormality in the 12-lead electrocardiogram (ECG) [including but not limited
             to Bazett's corrected QT (QTcB) interval &gt;450 milliseconds (msec) for men and &gt;470
             msec for women]

          -  have a history within the last 2 years or presence of cardiovascular, respiratory,
             hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders
             capable of significantly altering the absorption, metabolism, or elimination of drugs;
             of constituting a risk when taking the study medication; or of interfering with the
             interpretation of data

          -  have a history of drug or alcohol abuse, or regularly use known drugs of abuse

          -  show evidence of human immunodeficiency virus infection and/or positive human
             immunodeficiency virus (HIV) antibodies

          -  show evidence of hepatitis B and/or positive hepatitis B surface antigen

          -  intend to use over-the-counter or prescription medication within 14 days prior to
             dosing or during the study

          -  use of herbal supplements, grapefruit juice, grapefruits, Seville orange juice,
             Seville oranges, or Starfruit within 7 days prior to study dosing or intended use
             during the study

          -  have donated blood of more than 450 milliliters (mL) within the last 3 months

          -  have an average weekly alcohol intake that exceeds 21 units per week (males) and 14
             units per week (females), or are unwilling to stop alcohol consumption from prior to
             dosing until the completion of each study period [ unit = 12 ounces (oz) or 360 mL of
             beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits]

        Applicable for Part A only:

        • have known allergies to lignocaine, adrenaline, tetracycline, or related compounds, which
        will be used in the skin biopsy procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 2, 2011</study_first_submitted>
  <study_first_submitted_qc>June 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2011</study_first_posted>
  <results_first_submitted>September 27, 2017</results_first_submitted>
  <results_first_submitted_qc>August 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2019</results_first_posted>
  <last_update_submitted>August 3, 2018</last_update_submitted>
  <last_update_submitted_qc>August 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Part A: single period, single dose pilot assessed safety, tolerability. Part B: 4-period crossover evaluated bioavailability of 2 drug formulations. Part B, Period (P) 4 participants (pts) separated into 2 cohorts, received drug under fed (P4a) or fasted (P4b) conditions. Pts who withdrew or were withdrawn prior to completing P3 were replaced.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LY2584702</title>
          <description>Participants enrolled in Part A of the study received a single dose of 25 milligrams (mg) LY2584702 (LY) reference formulation [RF (capsule)] in a fasted state on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants enrolled in Part A of the study received placebo in a fasted state on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>10 mg LY TF, Placebo, 50 mg LY TF, 50 mg LY TF Fed</title>
          <description>Participants enrolled in Part B of the study received a single dose of 10 mg LY2584702 test formulation [TF (tablet)], placebo, and 50 mg LY2584702 TF in a fasted state, on Day 1 of Periods 1, 2, and 3, respectively and 50 mg LY2584702 TF in a fed state in Period 4a, Day 1. There was a washout of at least 3 days between periods.</description>
        </group>
        <group group_id="P4">
          <title>Placebo, 50 mg LY RF, 50 mg LY TF, 50 mg LY TF Fed</title>
          <description>Participants enrolled in Part B of the study received a single dose of placebo, 50 mg LY2584702 RF, and 50 mg LY2584702 TF in a fasted state, on Day 1 of Periods 1, 2, and 3, respectively and 50 mg LY2584702 TF in a fed state in Period 4a, Day 1. There was a washout of at least 3 days between periods.</description>
        </group>
        <group group_id="P5">
          <title>Placebo, 50 mg LY RF, 50 mg LY TF, 200 mg LY TF Fasted</title>
          <description>Participants enrolled in Part B of the study received a single dose of placebo, 50 mg LY2584702 RF, and 50 mg LY2584702 TF in a fasted state, on Day 1 of Periods 1, 2, and 3, respectively and 200 mg LY2584702 TF in a fasted state in Period 4b, Day 1. There was a washout of at least 3 days between periods.</description>
        </group>
        <group group_id="P6">
          <title>10 mg LY TF, 50 mg LY RF, 50 mg LY TF, 50 mg LY TF Fed</title>
          <description>Participants enrolled in Part B of the study received a single dose of 10 mg LY2584702 TF, 50 mg LY2584702 RF, and 50 mg LY2584702 TF in a fasted state, on Day 1 of Periods 1, 2, and 3, respectively and 50 mg LY2584702 TF in a fed state in Period 4a, Day 1. There was a washout of at least 3 days between periods.</description>
        </group>
        <group group_id="P7">
          <title>10 mg LY TF, 50 mg LY RF, 50 mg LY TF, 200 mg LY TF Fasted</title>
          <description>Participants enrolled in Part B of the study received a single dose of 10 mg LY2584702 TF, 50 mg LY2584702 RF, and 50 mg LY2584702 TF in a fasted state, on Day 1 of Periods 1, 2, and 3, respectively and 200 mg LY2584702 TF in a fasted state in Period 4b, Day 1. There was a washout of at least 3 days between periods.</description>
        </group>
        <group group_id="P8">
          <title>10 mg LY TF, 50 mg LY RF, 50 mg LY TF, Placebo Fasted</title>
          <description>Participants enrolled in Part B of the study received a single dose of 10 mg LY2584702 TF, 50 mg LY2584702 RF, and 50 mg LY2584702 TF in a fasted state, on Day 1 of Periods 1, 2, and 3, respectively and placebo in a fasted state in Period 4b, Day 1. There was a washout of at least 3 days between periods.</description>
        </group>
        <group group_id="P9">
          <title>10 mg LY TF, 50 mg LY RF, Placebo, 200 mg LY TF Fasted</title>
          <description>Participants enrolled in Part B of the study received a single dose of 10 mg LY2584702 TF, 50 mg LY2584702 RF, and placebo in a fasted state, on Day 1 of Periods 1, 2, and 3, respectively and 200 mg LY2584702 TF in a fasted state in Period 4b, Day 1. There was a washout of at least 3 days between periods.</description>
        </group>
        <group group_id="P10">
          <title>200 mg LY TF Fasted</title>
          <description>Participant enrolled in Part B, Period 4b of the study received a single dose of 200 mg LY2584702 TF in a fasted state on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (Period 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3">Replacement participant repeated Periods 1, 2 to fulfill treatment arm comparison requirements.</participants>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Pts completed one period and did not enter washout for Part A.</participants>
                <participants group_id="P2" count="0">Pts completed one period and did not enter washout for Part A.</participants>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (Period 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2">One participant discontinued Washout Period 2 and was replaced in Period 1.</participants>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Third Intervention (Period 3)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="7">Replacement pts repeated Period (P) 3 to fulfill requirement for P3 versus P4a comparison.</participants>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="5">Two participants (pts) discontinued Washout P3 and were replaced in P3.</participants>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Forth Intervention (Period 4a/4b)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1">One pt was enrolled directly into P4b to fulfill requirement for safety and tolerability assessment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A (LY2584702)</title>
          <description>Participants enrolled in Part A of the study received a single dose of 25 milligrams (mg) LY2584702 (LY) reference formulation [RF (capsule)] in a fasted state on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Part A (Placebo)</title>
          <description>Participants enrolled in Part A of the study received placebo in a fasted state on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>10 mg LY TF, Placebo, 50 mg LY TF, 50 mg LY TF Fed</title>
          <description>Participants enrolled in Part B of the study received a single dose of 10 mg LY2584702 test formulation [TF (tablet)], placebo, and 50 mg LY2584702 TF in a fasted state, on Day 1 of Periods 1, 2, and 3, respectively and 50 mg LY2584702 TF in a fed state in Period 4a, Day 1. There was a washout of at least 3 days between periods.</description>
        </group>
        <group group_id="B4">
          <title>Placebo, 50 mg LY RF, 50 mg LY TF, 50 mg LY TF Fed</title>
          <description>Participants enrolled in Part B of the study received a single dose of placebo, 50 mg LY2584702 RF, and 50 mg LY2584702 TF in a fasted state, on Day 1 of Periods 1, 2, and 3, respectively and 50 mg LY2584702 TF in a fed state in Period 4a, Day 1. There was a washout of at least 3 days between periods.</description>
        </group>
        <group group_id="B5">
          <title>Placebo, 50 mg LY RF, 50 mg LY TF, 200 mg LY TF Fasted</title>
          <description>Participants enrolled in Part B of the study received a single dose of placebo, 50 mg LY2584702 RF, and 50 mg LY2584702 TF in a fasted state, on Day 1 of Periods 1, 2, and 3, respectively and 200 mg LY2584702 TF in a fasted state in Period 4b, Day 1. There was a washout of at least 3 days between periods.</description>
        </group>
        <group group_id="B6">
          <title>10 mg LY TF, 50 mg LY RF, 50 mg LY TF, 50 mg LY TF Fed</title>
          <description>Participants enrolled in Part B of the study received a single dose of 10 mg LY2584702 TF, 50 mg LY2584702 RF, and 50 mg LY2584702 TF in a fasted state, on Day 1 of Periods 1, 2, and 3, respectively and 50 mg LY2584702 TF in a fed state in Period 4a, Day 1. There was a washout of at least 3 days between periods.</description>
        </group>
        <group group_id="B7">
          <title>10 mg LY TF, 50 mg LY RF, 50 mg LY TF, 200 mg LY TF Fasted</title>
          <description>Participants enrolled in Part B of the study received a single dose of 10 mg LY2584702 TF, 50 mg LY2584702 RF, and 50 mg LY2584702 TF in a fasted state, on Day 1 of Periods 1, 2, and 3, respectively and 200 mg LY2584702 TF in a fasted state in Period 4b, Day 1. There was a washout of at least 3 days between periods.</description>
        </group>
        <group group_id="B8">
          <title>10 mg LY TF, 50 mg LY RF, 50 mg LY TF, Placebo Fasted</title>
          <description>Participants enrolled in Part B of the study received a single dose of 10 mg LY2584702 TF, 50 mg LY2584702 RF, and 50 mg LY2584702 TF in a fasted state, on Day 1 of Periods 1, 2, and 3, respectively and placebo in a fasted state in Period 4b, Day 1. There was a washout of at least 3 days between periods.</description>
        </group>
        <group group_id="B9">
          <title>10 mg LY TF, 50 mg LY RF, Placebo, 200 mg LY TF Fasted</title>
          <description>Participants enrolled in Part B of the study received a single dose of 10 mg LY2584702 TF, 50 mg LY2584702 RF, and placebo in a fasted state, on Day 1 of Periods 1, 2, and 3, respectively and 200 mg LY2584702 TF in a fasted state in Period 4b, Day 1. There was a washout of at least 3 days between periods.</description>
        </group>
        <group group_id="B10">
          <title>200 mg LY TF Fasted</title>
          <description>Participant enrolled in Part B, Period 4b of the study received a single dose of 200 mg LY2584702 TF in a fasted state on Day 1.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="7"/>
            <count group_id="B7" value="3"/>
            <count group_id="B8" value="1"/>
            <count group_id="B9" value="1"/>
            <count group_id="B10" value="1"/>
            <count group_id="B11" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.9" spread="7.3"/>
                    <measurement group_id="B2" value="24" spread="4.2"/>
                    <measurement group_id="B3" value="44" spread="25.5"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="28" spread="8.2"/>
                    <measurement group_id="B6" value="34" spread="6.1"/>
                    <measurement group_id="B7" value="34" spread="8.9"/>
                    <measurement group_id="B8" value="28"/>
                    <measurement group_id="B9" value="35"/>
                    <measurement group_id="B10" value="28"/>
                    <measurement group_id="B11" value="32.6" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax)</title>
        <description>The Cmax following a single oral dose of LY2584702 test formulation [TF (tablet)] or reference formulation [RF (capsule)] is reported.</description>
        <time_frame>Part A: Day 1 and Part B: Periods 1 to 4, Day 1 [Predose, 1 hour (h), 3 h, 4 h, 6 h, 10 h, 24 h, 48 h postdose]</time_frame>
        <population>Randomized participants in Part A or B of the study who had evaluable Cmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg LY2584702 RF Fasted</title>
            <description>Participants received a 25 milligram (mg) LY2584702 RF orally in a fasted state on Day 1 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2584702 TF Fasted</title>
            <description>Participants received 10 mg of LY2584702 TF orally in a fasted state, in Period 1, Day 1 of Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>50 mg LY2584702 RF Fasted</title>
            <description>Participants received 50 mg of LY2584702 RF orally in a fasted state, in Period 2, Day 1 of Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2584702 TF Fasted</title>
            <description>Participants received 50 mg of LY2584702 TF orally in a fasted state, in Period 3, Day 1 of Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>50 mg LY2584702 TF Fed</title>
            <description>Participants received 50 mg of LY2584702 TF orally in a fed state, in Period 4a, Day 1 of Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>200 mg LY2584702 TF Fasted</title>
            <description>Participants received 200 mg of LY2584702 TF orally in a fasted state, in Period 4b, Day 1 of Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax)</title>
          <description>The Cmax following a single oral dose of LY2584702 test formulation [TF (tablet)] or reference formulation [RF (capsule)] is reported.</description>
          <population>Randomized participants in Part A or B of the study who had evaluable Cmax data.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266.83" spread="71"/>
                    <measurement group_id="O2" value="198.22" spread="26"/>
                    <measurement group_id="O3" value="481.11" spread="39"/>
                    <measurement group_id="O4" value="668.87" spread="26"/>
                    <measurement group_id="O5" value="794.13" spread="27"/>
                    <measurement group_id="O6" value="1486.5" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics, Area Under the Concentration-Time Curve (AUC)</title>
        <description>AUC from time 0 to the time of the last quantifiable concentration [AUC(0-tlast)] and AUC from time 0 to infinity [AUC(0-inf)] following a single oral dose of LY2584702 test formulation [TF (tablet)] or reference formulation [RF (capsule)] is reported.</description>
        <time_frame>Part A: Day 1 and Part B: Periods 1 to 4, Day 1 [Predose, 1 hour (h), 3 h, 4 h, 6 h, 10 h, 24 h, 48 h postdose]</time_frame>
        <population>Randomized participants in Part A or B of the study who had evaluable AUC data.</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg LY2584702 RF Fasted</title>
            <description>Participants received a 25 milligram (mg) LY2584702 RF orally in a fasted state on Day 1 in Part A of the study.</description>
          </group>
          <group group_id="O2">
            <title>10 mg LY2584702 TF Fasted</title>
            <description>Participants received 10 mg of LY2584702 TF orally in a fasted state, in Period 1, Day 1 of Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>50 mg LY2584702 RF Fasted</title>
            <description>Participants received 50 mg of LY2584702 RF orally in a fasted state, in Period 2, Day 1 of Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2584702 TF Fasted</title>
            <description>Participants received 50 mg of LY2584702 TF orally in a fasted state, in Period 3, Day 1 of Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>50 mg LY2584702 TF Fed</title>
            <description>Participants received 50 mg of LY2584702 TF orally in a fed state, in Period 4a, Day 1 of Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>200 mg LY2584702 TF Fasted</title>
            <description>Participants received 200 mg of LY2584702 TF orally in a fasted state, in Period 4b, Day 1 of Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics, Area Under the Concentration-Time Curve (AUC)</title>
          <description>AUC from time 0 to the time of the last quantifiable concentration [AUC(0-tlast)] and AUC from time 0 to infinity [AUC(0-inf)] following a single oral dose of LY2584702 test formulation [TF (tablet)] or reference formulation [RF (capsule)] is reported.</description>
          <population>Randomized participants in Part A or B of the study who had evaluable AUC data.</population>
          <units>nanograms*hour per milliliter (ng*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-tlast)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1740" spread="63"/>
                    <measurement group_id="O2" value="1070" spread="26"/>
                    <measurement group_id="O3" value="3310" spread="43"/>
                    <measurement group_id="O4" value="4210" spread="25"/>
                    <measurement group_id="O5" value="5560" spread="30"/>
                    <measurement group_id="O6" value="10300" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-inf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1860" spread="58"/>
                    <measurement group_id="O2" value="1110" spread="27"/>
                    <measurement group_id="O3" value="3530" spread="43"/>
                    <measurement group_id="O4" value="4430" spread="25"/>
                    <measurement group_id="O5" value="5620" spread="29"/>
                    <measurement group_id="O6" value="10900" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Baseline-Adjusted Change-From-Predose in the Concentration of Lipids (Total Cholesterol)</title>
        <description>Baseline-adjusted change-from-predose in lipid concentrations were measured to assess the LY2584702 effect on lipids under different fed states. The 50-milligram (mg) LY2584702 test formulation [TF (tablet)] was the only dose and formulation administered in both the fasted and fed states for comparison. Therefore, changes in total cholesterol after single oral doses of placebo, 10-mg, or 200-mg LY2584702 TF or 25-mg or 50-mg LY2584702 reference formulation [RF (capsule)] were not calculated. The baseline-adjusted change-from-predose in total cholesterol levels in the fasted and fed state following a single 50-mg LY2584702 TF dose is reported. Baseline was Day -1 of Period 1 for Period 3 fasted state and baseline was Day -1 of Period 4a for Period 4a fed state. Least squares (LS) means was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, time, treatment by time, and participant.</description>
        <time_frame>Part B: Baseline [Periods 1 and 4a (Day -1)], Periods 3, 4a (Day 1). Lipid concentration measurements were performed at time point 0 and 1 hour (h), 3 h, 4 h, 6 h, 10 h, and 24 h.</time_frame>
        <population>Randomized participants (pts) in Part B of study who had both baseline and postdose total cholesterol measurements. Pts not analyzed for baseline-adjusted change-from-predose total cholesterol levels after single dose placebo, 10-mg, or 200-mg LY2584702 TF or 25-mg or 50-mg LY2584702 RF since they weren’t administered in both fasted and fed state.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg LY2584702 TF Fasted</title>
            <description>Participants received 50 mg of LY2584702 TF orally in a fasted state, in Period 3, Day 1 of Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>50 mg LY2584702 TF Fed</title>
            <description>Participants received 50 mg of LY2584702 TF orally in a fed state, in Period 4a, Day 1 of Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Baseline-Adjusted Change-From-Predose in the Concentration of Lipids (Total Cholesterol)</title>
          <description>Baseline-adjusted change-from-predose in lipid concentrations were measured to assess the LY2584702 effect on lipids under different fed states. The 50-milligram (mg) LY2584702 test formulation [TF (tablet)] was the only dose and formulation administered in both the fasted and fed states for comparison. Therefore, changes in total cholesterol after single oral doses of placebo, 10-mg, or 200-mg LY2584702 TF or 25-mg or 50-mg LY2584702 reference formulation [RF (capsule)] were not calculated. The baseline-adjusted change-from-predose in total cholesterol levels in the fasted and fed state following a single 50-mg LY2584702 TF dose is reported. Baseline was Day -1 of Period 1 for Period 3 fasted state and baseline was Day -1 of Period 4a for Period 4a fed state. Least squares (LS) means was calculated using mixed model repeating measures (MMRM) and adjusted for treatment, time, treatment by time, and participant.</description>
          <population>Randomized participants (pts) in Part B of study who had both baseline and postdose total cholesterol measurements. Pts not analyzed for baseline-adjusted change-from-predose total cholesterol levels after single dose placebo, 10-mg, or 200-mg LY2584702 TF or 25-mg or 50-mg LY2584702 RF since they weren’t administered in both fasted and fed state.</population>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.62" lower_limit="-11.53" upper_limit="0.30"/>
                    <measurement group_id="O2" value="-2.38" lower_limit="-9.91" upper_limit="5.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.00" lower_limit="-9.91" upper_limit="1.91"/>
                    <measurement group_id="O2" value="-1.75" lower_limit="-9.29" upper_limit="5.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.15" lower_limit="-10.07" upper_limit="1.76"/>
                    <measurement group_id="O2" value="-1.88" lower_limit="-9.41" upper_limit="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.77" lower_limit="-10.68" upper_limit="1.14"/>
                    <measurement group_id="O2" value="0.75" lower_limit="-6.79" upper_limit="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.23" lower_limit="-15.14" upper_limit="-3.32"/>
                    <measurement group_id="O2" value="-5.25" lower_limit="-12.79" upper_limit="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.85" lower_limit="-14.76" upper_limit="-2.93"/>
                    <measurement group_id="O2" value="-8.75" lower_limit="-16.29" upper_limit="-1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: QT Interval Corrected by Fridericia's Formula (QTcF) Change From Baseline to Day 1</title>
        <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and is calculated from electrocardiogram (ECG) data. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between 2 R waves. Using Fridericia's formula: QTcF = QT/RR^0.33. The QTcF after single oral doses of LY2584702 reference formulation [RF (capsule)] were administered in a fasted state are reported at baseline (Day 1, Predose) and 3 hours (h), 4 h, 6 h, and 24 h postdose.</description>
        <time_frame>Part A: Baseline [Day 1 (Predose)] and Day 1 (3 h, 4 h, 6 h, and 24 h postdose)</time_frame>
        <population>Randomized participants in Part A of the study who had both baseline and postdose ECG assessments at each time point. Data was not collected for Placebo group due to insufficient participants (N=2).</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg LY2584702 RF Fasted</title>
            <description>Participants received a 25 milligram (mg) LY2584702 RF orally, in a fasted state on Day 1 in Part A of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: QT Interval Corrected by Fridericia's Formula (QTcF) Change From Baseline to Day 1</title>
          <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and is calculated from electrocardiogram (ECG) data. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between 2 R waves. Using Fridericia's formula: QTcF = QT/RR^0.33. The QTcF after single oral doses of LY2584702 reference formulation [RF (capsule)] were administered in a fasted state are reported at baseline (Day 1, Predose) and 3 hours (h), 4 h, 6 h, and 24 h postdose.</description>
          <population>Randomized participants in Part A of the study who had both baseline and postdose ECG assessments at each time point. Data was not collected for Placebo group due to insufficient participants (N=2).</population>
          <units>milliseconds (ms)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402.8" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="394.8" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="396.6" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395.7" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="396.1" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Average Time-Matched QT Interval Corrected by Fridericia's Formula (QTcF) Change From Baseline to Day 1</title>
        <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and is calculated from electrocardiogram (ECG) data. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between 2 R waves. Using Fridericia's formula: QTcF = QT/RR^0.33. The QTcF after single oral doses of LY2584702 test formulation [TF (tablet)], LY2584702 reference formulation [RF (capsule)], or placebo were administered in a fasted or fed state are reported at baseline (time-matched Day -1 QTcF) and 3 hours (h), 4 h, 6 h, and 24 h postdose. Day 1, Hour 24 was time-matched with Day-1, Hour 0.</description>
        <time_frame>Part B: Baseline [Period 1 (Day -1)] and Periods 1 to 4 (Day 1). Electrocardiograms (ECG) were performed at time point 0 and 3 h, 4 h, 6 h, and 24 h.</time_frame>
        <population>Randomized participants in Part B of the study who had both baseline and postdose ECG assessments at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg LY2584702 TF Fasted</title>
            <description>Participants received 10 milligrams (mg) of LY2584702 TF orally in a fasted state in Period 1, Day 1 of Part B of the study.</description>
          </group>
          <group group_id="O2">
            <title>50 mg LY2584702 RF Fasted</title>
            <description>Participants received 50 mg of LY2584702 RF orally in a fasted state in Period 2, Day 1 of Part B of the study.</description>
          </group>
          <group group_id="O3">
            <title>50 mg LY2584702 TF Fasted</title>
            <description>Participants received 50 mg of LY2584702 TF orally in a fasted state in Period 3, Day 1 of Part B of the study.</description>
          </group>
          <group group_id="O4">
            <title>50 mg LY2584702 TF Fed</title>
            <description>Participants received 50 mg of LY2584702 TF orally in a fed state in Period 4a, Day 1 of Part B of the study.</description>
          </group>
          <group group_id="O5">
            <title>200 mg LY2584702 TF Fasted</title>
            <description>Participants received 200 mg of LY2584702 TF orally in a fasted state in Period 4b, Day 1 of Part B of the study.</description>
          </group>
          <group group_id="O6">
            <title>Placebo (Part B)</title>
            <description>Participants received placebo orally in a fasted state, in Periods 1 to 4, Day 1 of Part B of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Average Time-Matched QT Interval Corrected by Fridericia's Formula (QTcF) Change From Baseline to Day 1</title>
          <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and is calculated from electrocardiogram (ECG) data. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between 2 R waves. Using Fridericia's formula: QTcF = QT/RR^0.33. The QTcF after single oral doses of LY2584702 test formulation [TF (tablet)], LY2584702 reference formulation [RF (capsule)], or placebo were administered in a fasted or fed state are reported at baseline (time-matched Day -1 QTcF) and 3 hours (h), 4 h, 6 h, and 24 h postdose. Day 1, Hour 24 was time-matched with Day-1, Hour 0.</description>
          <population>Randomized participants in Part B of the study who had both baseline and postdose ECG assessments at each time point.</population>
          <units>milliseconds (ms)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day-1, Hour 0 (time-matched baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="419.1" spread="21.0"/>
                    <measurement group_id="O2" value="413.6" spread="21.5"/>
                    <measurement group_id="O3" value="417.1" spread="18.9"/>
                    <measurement group_id="O4" value="428.0" spread="11.2"/>
                    <measurement group_id="O5" value="415.8" spread="23.5"/>
                    <measurement group_id="O6" value="416.4" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, Hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416.4" spread="17.8"/>
                    <measurement group_id="O2" value="413.3" spread="23.0"/>
                    <measurement group_id="O3" value="414.4" spread="17.7"/>
                    <measurement group_id="O4" value="407.8" spread="16.2"/>
                    <measurement group_id="O5" value="413.1" spread="22.1"/>
                    <measurement group_id="O6" value="412.1" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-1, Hour 3 (time-matched baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416.1" spread="21.0"/>
                    <measurement group_id="O2" value="412.4" spread="19.8"/>
                    <measurement group_id="O3" value="413.8" spread="18.2"/>
                    <measurement group_id="O4" value="423.3" spread="14.8"/>
                    <measurement group_id="O5" value="415.2" spread="22.0"/>
                    <measurement group_id="O6" value="415.7" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413.6" spread="17.8"/>
                    <measurement group_id="O2" value="410.6" spread="23.2"/>
                    <measurement group_id="O3" value="409.2" spread="16.2"/>
                    <measurement group_id="O4" value="402.6" spread="10.0"/>
                    <measurement group_id="O5" value="409.9" spread="22.1"/>
                    <measurement group_id="O6" value="412.3" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-1, Hour 4 (time-matched baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="415.5" spread="20.6"/>
                    <measurement group_id="O2" value="413.1" spread="20.7"/>
                    <measurement group_id="O3" value="414.6" spread="18.3"/>
                    <measurement group_id="O4" value="420.7" spread="10.1"/>
                    <measurement group_id="O5" value="418.3" spread="24.2"/>
                    <measurement group_id="O6" value="413.4" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414.8" spread="17.7"/>
                    <measurement group_id="O2" value="412.0" spread="21.0"/>
                    <measurement group_id="O3" value="409.2" spread="14.0"/>
                    <measurement group_id="O4" value="407.3" spread="12.1"/>
                    <measurement group_id="O5" value="413.3" spread="20.4"/>
                    <measurement group_id="O6" value="415.2" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day-1, Hour 6 (time-matched baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="417.1" spread="20.6"/>
                    <measurement group_id="O2" value="415.0" spread="19.8"/>
                    <measurement group_id="O3" value="417.6" spread="19.3"/>
                    <measurement group_id="O4" value="420.5" spread="12.5"/>
                    <measurement group_id="O5" value="422.3" spread="24.0"/>
                    <measurement group_id="O6" value="418.1" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413.2" spread="14.8"/>
                    <measurement group_id="O2" value="410.6" spread="18.1"/>
                    <measurement group_id="O3" value="409.6" spread="14.3"/>
                    <measurement group_id="O4" value="414.8" spread="11.5"/>
                    <measurement group_id="O5" value="415.6" spread="15.8"/>
                    <measurement group_id="O6" value="412.4" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="415.4" spread="19.4"/>
                    <measurement group_id="O2" value="408.9" spread="19.0"/>
                    <measurement group_id="O3" value="409.1" spread="13.9"/>
                    <measurement group_id="O4" value="411.1" spread="13.5"/>
                    <measurement group_id="O5" value="409.0" spread="17.9"/>
                    <measurement group_id="O6" value="409.0" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo orally in fasted state on Day 1 in Part A and Periods 1 to 4, Day 1 in Part B of the study.</description>
        </group>
        <group group_id="E2">
          <title>25 mg LY2584702 RF Fasted</title>
          <description>Participants received a 25 milligram (mg) LY2584702 reference formulation [RF (capsule)] orally in a fasted state on Day 1 in Part A of the study.</description>
        </group>
        <group group_id="E3">
          <title>10 mg LY2584702 TF Fasted</title>
          <description>Participants received 10 mg of LY2584702 test formulation [TF (tablet)] orally in a fasted state, in Period 1, Day 1 of Part B of the study.</description>
        </group>
        <group group_id="E4">
          <title>50 mg LY2584702 RF Fasted</title>
          <description>Participants received 50 mg of LY2584702 RF orally in a fasted state, in Period 2, Day 1 of Part B of the study.</description>
        </group>
        <group group_id="E5">
          <title>50 mg LY2584702 TF Fasted</title>
          <description>Participants received 50 mg of LY2584702 TF orally in a fasted state, in Period 3, Day 1 of Part B of the study.</description>
        </group>
        <group group_id="E6">
          <title>50 mg LY2584702 TF Fed</title>
          <description>Participants received 50 mg of LY2584702 TF orally in a fed state, in Period 4a, Day 1 of Part B of the study.</description>
        </group>
        <group group_id="E7">
          <title>200 mg LY2584702 TF Fasted</title>
          <description>Participants received 200 mg of LY2584702 TF orally in a fasted state, in Period 4b, Day 1 of Part B of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

